P553: A PHASE 2, OPEN-LABEL, MULTIARM, MULTICENTER STUDY TO EVALUATE MAGROLIMAB COMBINED WITH ANTILEUKEMIA THERAPIES FOR FIRST-LINE, RELAPSED/REFRACTORY, OR MAINTENANCE TREATMENT OF ACUTE MYELOID LEUKEMIA. (23rd June 2022) - Vyas, P.; Daver, N. G.; Chao, M. P.; Xing, G.; Renard, C.; Ramsingh, G.; Wei, A. H.; Sallman, D. A.